News | Computed Tomography (CT) | November 06, 2019

Radiology: Cardiothoracic Imaging Publishes Special Report on Vaping

Radiology: Cardiothoracic Imaging has published a special report on lung injury resulting from the use of electronic cigarettes (e-cigarettes), or “vaping.”

Image by Lindsay Fox from Pixabay

November 6, 2019 — Radiology: Cardiothoracic Imaging has published a special report on lung injury resulting from the use of electronic cigarettes (e-cigarettes), or “vaping.” Authors Suhny Abbara, M.D., FACR, MSCCT and Fernando Uliana Kay, M.D., Ph.D., from the Department of Radiology at UT Southwestern Medical Center in Dallas, Texas, aim to raise awareness among radiologists and other medical professionals on how to identify e-cigarette or vaping product use-associated lung injury (EVALI).

“Radiologists will continue to play an important role in recognizing this emerging entity,” said Abbara, who is also the editor of Radiology: Cardiothoracic Imaging. “We encourage the medical imaging community to produce scientific evidence and medical knowledge to help advance our collective understanding of the effects of e-cigarette use on the lungs and other organ systems.”

E-cigarettes act by delivering nicotine, flavorings and other additives in aerosol form. According to the CDC, more than 9 million adults in the U.S. use e-cigarettes, and vaping has become especially popular among teens. The 2018 National Youth Tobacco Survey reported that in 2018 more than 3.6 million middle and high school students were using e-cigarettes.

The Centers for Disease Control and Prevention (CDC), the U.S. Food and Drug Administration and state and local health departments have started an investigation into the recent outbreak of lung injury associated with the use of e-cigarettes. As of Oct. 22, 2019, 1,604 cases have been reported from 49 U.S. states, the District of Columbia, and one U.S. territory. Thirty-four cases have resulted in death. However, these numbers likely underestimate the true incidence and prevalence of disease due to lack of recognition and reporting of vaping-associated lung injury.

In the special report, Abbara and Kay summarize recent cases from the literature and illustrate some of the radiographic and CT findings of lung injury with a clinical case of a 24-year-old male patient with past medical history of asthma, who presented with shortness of breath, productive cough, chest pain and fever for one week. The patient reported current daily use of e-cigarettes (with tobacco) and marijuana, without substantial change in recent vaping habits. He had high white cell and platelet counts. His chest X-ray showed ground-glass and reticular, or netlike, opacities in both lungs.

CT findings included ground glass opacities and pulmonary consolidation with relative subpleural sparing. Histologic specimens obtained from the right lower lobe at biopsy were suggestive of lipoid pneumonia. The patient was given steroids with a presumptive diagnosis of lung injury associated with e-cigarette use.

“The diagnosis of lung injury due to e-cigarette use should be a differential possibility in patients presenting with bilateral lung opacities on radiographs or ground-glass opacities on chest CT images and exposure to e-cigarette products within 90 days of the presentation,” Abbara said.

The epidemiologic case definition of lung injury associated with e-cigarette use for surveillance purposes includes the presence of all the following criteria: use of e-cigarette or dabbing (butane hash oils) within 90 days before symptom onset, presence of pulmonary opacities on chest radiographs or ground-glass opacities on chest CT images, absence of pulmonary infection at initial workup, and no evidence of alternative plausible diagnoses.

The report outlines that research into vaping-associated lung injury should be approached as a team effort by members of multiple specialties, including pathologists, epidemiologists, pulmonologists and emergency physicians, but highlights the critical role of radiologists.

“It is crucial that radiologists drive some of the research initiatives to better understand the mechanisms of disease presentation, facilitating the diagnosis and management of these patients,” Abbara said.

For more information: www.rsna.org

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Getty Images

Feature | Coronavirus (COVID-19) | April 07, 2020 | By Melinda Taschetta-Millane and Dave Fornell
In an effort to keep the imaging field updated on the latest information being released on coronavirus (COVID-19), th
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2  The first of three clinical scenarios presented to the panel with final recommendations. Mild features refer to absence of significant pulmonary dysfunction or damage. Pre-test probability is based upon background prevalence of disease and may be further modified by individual’s exposure risk. The absence of resource constraints corresponds to sufficient availability of personnel, personal protective equipment, COVID-19 testing, hospital beds, and/or ve

 The first of three clinical scenarios presented to the panel with final recommendations. Mild features refer to absence of significant pulmonary dysfunction or damage. Pre-test probability is based upon background prevalence of disease and may be further modified by individual’s exposure risk. The absence of resource constraints corresponds to sufficient availability of personnel, personal protective equipment, COVID-19 testing, hospital beds, and/or ventilators with the need to rapidly triage patients. Contextual detail and considerations for imaging with CXR (chest radiography) versus CT (computed tomography) are presented in the text. (Pos=positive, Neg=negative, Mod=moderate). [Although not covered by this scenario and not shown in the figure, in the presence of significant resources constraints, there is no role for imaging of patients with mild features of COVID-19.] Image courtesy of the journal Radiology

News | Coronavirus (COVID-19) | April 07, 2020
April 7, 2020 — A multinational consens...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Chest CT findings of pediatric patients with COVID-19 on transaxial images. (a) Male, 2 months old, 2 days after symptom onset. Patchy ground-glass opacities GGO in the right lower lobe

Chest CT findings of pediatric patients with COVID-19 on transaxial images. Male, 2 months old, 2 days after symptom onset. Patchy ground-glass opacities GGO in the right lower lobe. Image courtesy of Radiology: Cardiothoracic Imaging

News | Coronavirus (COVID-19) | April 06, 2020
April 6, 2020 — Children and teenagers with COVID-19...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Sonogram taken under rib cage shows liver (grey) with curved diaphragm-lung border (white). Arrows point to vertical B lines (white) demonstrating diseased lung tissue. The more B lines the worse the disease. Healing is measured by reduction in the number of B lines.

Sonogram taken under rib cage shows liver (grey) with curved diaphragm-lung border (white). Arrows point to vertical B lines (white) demonstrating diseased lung tissue. The more B lines the worse the disease. Healing is measured by reduction in the number of B lines.

News | Coronavirus (COVID-19) | April 06, 2020
April 6, 2020 — Robert L.
Recommended best practices for nuclear imaging departments under the COVIF-19 pandemic have been issues by the ASNC and SNMMI. #COVID19 #ASNC #SNMMI #Coronavirus #SARScov2
News | Coronavirus (COVID-19) | April 03, 2020
April 3, 2020 — A new guidance document on best practices to maintain safety and minimize contamination in nuclear im
An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal.

An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal. Photo by Dave Fornell

Feature | Radiology Imaging | April 02, 2020 | By Katie Caron
A new year — and decade — offers the opportunity to reflect on the advancements and challenges of years gone by and p